Peptide Receipt
Tesamorelin · Checked 2026-07-25
PR-DRAFT-MS0L8LTI-2Q5F5M1A
Claim
“Tesamorelin burns visceral fat”
What people are actually reporting
Anecdotal · User-reported · Not clinical evidence
Here’s what keeps coming up in real user reports:
- visceral fat reduction
- growth hormone stimulation
- HIV lipodystrophy context
LESS CONSISTENT REPORTS
- High cost or difficulty obtaining it for non-medical reasons.
- Concerns about potential side effects like joint pain or insulin resistance.
The receipt
Mostly Supported
Confidence · High
Yes, Tesamorelin is specifically designed and FDA-approved to reduce visceral fat (the deep 'belly fat' around organs). However, this approval and most research only apply to people living with HIV who have lipodystrophy.
What the research says
Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analogue. Research across multiple Phase III trials confirms it reduces visceral fat in HIV patients.
Evidence level
- Human evidence
- Strong
- Animal evidence
- None
- Lab evidence
- None
- Registered trials
- 1
Sources
Research and educational information only. Not medical advice.